GlassScriptPhysician profile
Charles David Eldridge
NPI 1871162206
$7,661.36
in general payments reported to CMS, 2019-2025
26 companies · $2,040 in 2025
The $2,040 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $835 · 2022: $959 · 2023: $2,200 · 2024: $1,628 · 2025: $2,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,860 · Education: $7.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,860.02 |
| Education | $7.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,812.49 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $829.31 | 2022-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $797.04 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $673.35 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $507.84 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $506.14 | 2021-2025 | Caplyta |
| Alkermes, INC. | $503.13 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $482.68 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $270.45 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $227.85 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $204.75 | 2023-2025 | Auvelity, Sunosi |
| Jazz Pharmaceuticals INC. | $167.73 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $158.48 | 2021-2025 | Uzedy |
| Vanda Pharmaceuticals INC. | $112.94 | 2025 | Fanapt |
| Indivior INC. | $109.81 | 2022-2023 | Perseris |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $64.80 | 2021 | |
| Corium, LLC | $48.33 | 2022-2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $42.06 | 2022 | |
| Avanir Pharmaceuticals, INC. | $29.84 | 2022 | |
| Novo Nordisk INC | $19.31 | 2023 | Wegovy |
| Harmony Biosciences LLC | $18.58 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.99 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $16.42 | 2021 | |
| Pfizer INC. | $14.14 | 2023 | |
| Sunovion Pharmaceuticals INC. | $14.11 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.79 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Eldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.